HUE066802T2 - JAK kináz inhibitor észter és karbonát pirimidin vegyületek - Google Patents
JAK kináz inhibitor észter és karbonát pirimidin vegyületekInfo
- Publication number
- HUE066802T2 HUE066802T2 HUE20726591A HUE20726591A HUE066802T2 HU E066802 T2 HUE066802 T2 HU E066802T2 HU E20726591 A HUE20726591 A HU E20726591A HU E20726591 A HUE20726591 A HU E20726591A HU E066802 T2 HUE066802 T2 HU E066802T2
- Authority
- HU
- Hungary
- Prior art keywords
- carbonate
- ester
- kinase inhibitors
- pyrimidine compounds
- jak kinase
- Prior art date
Links
- FNKLZPHAAKLNBX-UHFFFAOYSA-N carbonic acid;pyrimidine Chemical class OC(O)=O.C1=CN=CN=C1 FNKLZPHAAKLNBX-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837829P | 2019-04-24 | 2019-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066802T2 true HUE066802T2 (hu) | 2024-09-28 |
Family
ID=70740750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20726591A HUE066802T2 (hu) | 2019-04-24 | 2020-04-23 | JAK kináz inhibitor észter és karbonát pirimidin vegyületek |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11155549B2 (https=) |
| EP (1) | EP3958969B1 (https=) |
| JP (1) | JP7470713B2 (https=) |
| AR (1) | AR118768A1 (https=) |
| CA (1) | CA3135383A1 (https=) |
| ES (1) | ES2974577T3 (https=) |
| HR (1) | HRP20240346T1 (https=) |
| HU (1) | HUE066802T2 (https=) |
| PL (1) | PL3958969T3 (https=) |
| TW (1) | TW202106682A (https=) |
| WO (1) | WO2020219639A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| TW202106681A (zh) * | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| US20210212962A1 (en) * | 2020-01-13 | 2021-07-15 | Sol-Gel Technologies Ltd. | Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases |
| CA3216017A1 (en) * | 2021-04-22 | 2022-10-27 | Shengjian Huang | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20070179125A1 (en) | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| CN104011050A (zh) | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (https=) * | 2014-08-21 | 2018-03-31 | ||
| ES2753159T3 (es) | 2015-05-28 | 2020-04-07 | Theravance Biopharma R&D Ip Llc | Compuestos de naftiridina como inhibidores de quinasa JAK |
| CA3020506A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2020108516A1 (zh) | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020108613A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| PL3958969T3 (pl) | 2019-04-24 | 2024-05-20 | Theravance Biopharma R&D Ip, Llc | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz |
| TW202106681A (zh) | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| CN113372364B (zh) | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
| CN113372351A (zh) | 2020-03-10 | 2021-09-10 | 明慧医药（杭州）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
-
2020
- 2020-04-23 PL PL20726591.9T patent/PL3958969T3/pl unknown
- 2020-04-23 ES ES20726591T patent/ES2974577T3/es active Active
- 2020-04-23 HR HRP20240346TT patent/HRP20240346T1/hr unknown
- 2020-04-23 TW TW109113575A patent/TW202106682A/zh unknown
- 2020-04-23 WO PCT/US2020/029465 patent/WO2020219639A1/en not_active Ceased
- 2020-04-23 JP JP2021562810A patent/JP7470713B2/ja active Active
- 2020-04-23 AR ARP200101152A patent/AR118768A1/es unknown
- 2020-04-23 CA CA3135383A patent/CA3135383A1/en active Pending
- 2020-04-23 HU HUE20726591A patent/HUE066802T2/hu unknown
- 2020-04-23 US US16/856,280 patent/US11155549B2/en active Active
- 2020-04-23 EP EP20726591.9A patent/EP3958969B1/en active Active
-
2021
- 2021-09-27 US US17/448,922 patent/US11845747B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11155549B2 (en) | 2021-10-26 |
| WO2020219639A1 (en) | 2020-10-29 |
| CA3135383A1 (en) | 2020-10-29 |
| US20220009926A1 (en) | 2022-01-13 |
| PL3958969T3 (pl) | 2024-05-20 |
| EP3958969C0 (en) | 2024-01-10 |
| JP2022529370A (ja) | 2022-06-21 |
| TW202106682A (zh) | 2021-02-16 |
| US20200339580A1 (en) | 2020-10-29 |
| EP3958969A1 (en) | 2022-03-02 |
| AR118768A1 (es) | 2021-10-27 |
| US11845747B2 (en) | 2023-12-19 |
| HRP20240346T1 (hr) | 2024-05-24 |
| JP7470713B2 (ja) | 2024-04-18 |
| EP3958969B1 (en) | 2024-01-10 |
| ES2974577T3 (es) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3958969T3 (pl) | Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL274037A (en) | A pyrimidine compound as a JAK kinase inhibitor | |
| IL280762A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA201807179B (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11202013064WA (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| EP3293177A4 (en) | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| EP3448852A4 (en) | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL | |
| IL292093A (en) | Thianopyrimidones as trpa1 inhibitors | |
| IL292095A (en) | Thianopyrimidones as trpa1 inhibitors | |
| EP3999064A4 (en) | Inhibitors of tyrosine kinase | |
| IL281599A (en) | TYK2 kinase inhibitors | |
| EP4011880A4 (en) | JAK KINASE INHIBITOR AND USE THEREOF | |
| EP3947369A4 (en) | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | |
| IL297624B2 (en) | Cycloalkyl pyrimidines as proportin inhibitors | |
| ZA202002825B (en) | Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| HK40037119A (en) | Pyrimidine compounds useful as tyrosine kinase inhibitors | |
| EP3727387A4 (en) | PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS | |
| HK40075155A (en) | Inhibitors of tyrosine kinase | |
| GB201914388D0 (en) | Kinase inhibitors |